Last reviewed · How we verify
Adipose derived, autologous mesenchymal stem cells
At a glance
| Generic name | Adipose derived, autologous mesenchymal stem cells |
|---|---|
| Also known as | AD-MSC |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Arthralgia
- Procedural pain
- Joint swelling
- Headache
- Influenza like illness
- Joint stiffness
- Post procedural contusion
- Fatigue
- Injection site pain
- Pyrexia
- Back pain
- Stiff knees
Key clinical trials
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars (PHASE1, PHASE2)
- "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
- A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects (PHASE1)
- Stem Cell Therapy for Early Alzheimer's Disease (PHASE1, PHASE2)
- Investigating the Efficacy of Autologous, Adipose-derived Mesenchymal Stem Cell Therapy for the Treatment of Sexual Function Impairment in Women Aged 40-50 (PHASE1, PHASE2)
- Angiographic Delivery of AD-MSC for Ulcerative Colitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: